Lipoprotein-associated phospholipase A₂, and subsequent cardiovascular events and mortality among patients with coronary heart disease

Abstract

Objective: The objective of this study is to evaluate the relevance of Lp-PLA₂ to risk prediction among coronary heart disease (CHD) patients.

Methods: Lp-PLA₂ activity was measured in 2538 CHD patients included in the Bezafibrate Infarction Prevention (BIP) study.

Results: Adjusting for patient characteristics and traditional risk factors, 1 standard deviation of Lp-PLA₂ was associated with a hazard ratio (HR) of 1.12 (95% confidence interval (CI): 1.00–1.25) for mortality and 1.03 (0.93–1.14) for cardiovascular events. Lp-PLA₂ did not significantly improve model discrimination, or calibration nor result in noteworthy reclassification.

Conclusions: Our results do not support added value of Lp-PLA₂ for predicting cardiovascular events or mortality among CHD patients beyond traditional risk factor.

Keywords:

• Cohort study
• risk factors
• risk prediction

Disclosure statement

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article. The Lp-PLA₂ sample kits were provided by Anton Jansen, diaDexus Inc. (San Francisco, CA) without charge. The supplier had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.